EP2421532A4 - Spiperone derivatives and methods of treating disorders - Google Patents

Spiperone derivatives and methods of treating disorders

Info

Publication number
EP2421532A4
EP2421532A4 EP09818115A EP09818115A EP2421532A4 EP 2421532 A4 EP2421532 A4 EP 2421532A4 EP 09818115 A EP09818115 A EP 09818115A EP 09818115 A EP09818115 A EP 09818115A EP 2421532 A4 EP2421532 A4 EP 2421532A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating disorders
spiperone
derivatives
spiperone derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09818115A
Other languages
German (de)
French (fr)
Other versions
EP2421532A2 (en
Inventor
William B Guggino
Erik M Schwiebert
Lihua Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP2421532A2 publication Critical patent/EP2421532A2/en
Publication of EP2421532A4 publication Critical patent/EP2421532A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP09818115A 2008-10-02 2009-10-01 Spiperone derivatives and methods of treating disorders Withdrawn EP2421532A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10213508P 2008-10-02 2008-10-02
PCT/US2009/005441 WO2010039260A2 (en) 2008-10-02 2009-10-01 Spiperone derivatives and methods of treating disorders

Publications (2)

Publication Number Publication Date
EP2421532A2 EP2421532A2 (en) 2012-02-29
EP2421532A4 true EP2421532A4 (en) 2012-07-04

Family

ID=42074071

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09818115A Withdrawn EP2421532A4 (en) 2008-10-02 2009-10-01 Spiperone derivatives and methods of treating disorders

Country Status (3)

Country Link
US (1) US8664237B2 (en)
EP (1) EP2421532A4 (en)
WO (1) WO2010039260A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7002335B2 (en) * 2015-07-03 2022-01-20 エフ．ホフマン－ラ ロシュ アーゲー Triaza-spirodecanone as a DDR1 inhibitor
RU2740378C1 (en) * 2020-02-11 2021-01-13 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Medicinal agent stimulating pulmonary endothelial regeneration in chronic obstructive pulmonary disease
CN113480536B (en) * 2021-04-21 2024-02-23 中国人民解放军海军军医大学 Spiropiperidone derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693645A (en) * 1992-12-23 1997-12-02 Beth Israel Deaconess Medical Center, Inc. Use of spiperone or spiperone derivatives as immunosuppressant agents
WO2009074575A2 (en) * 2007-12-10 2009-06-18 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693645A (en) * 1992-12-23 1997-12-02 Beth Israel Deaconess Medical Center, Inc. Use of spiperone or spiperone derivatives as immunosuppressant agents
WO2009074575A2 (en) * 2007-12-10 2009-06-18 Novartis Ag Organic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIANG LIHUA ET AL: "Spiperone, identified through compound screening, activates calcium-dependent chloride secretion in the airway.", AMERICAN JOURNAL OF PHYSIOLOGY. CELL PHYSIOLOGY JAN 2009 LNKD- PUBMED:18987251, vol. 296, no. 1, January 2009 (2009-01-01), pages C131 - C141, XP002676454, ISSN: 0363-6143 *

Also Published As

Publication number Publication date
US8664237B2 (en) 2014-03-04
WO2010039260A3 (en) 2010-08-05
WO2010039260A2 (en) 2010-04-08
EP2421532A2 (en) 2012-02-29
US20120029005A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
HK1254895A1 (en) Benzylbenzene derivatives and methods of use
EP2293800A4 (en) Compositions and methods for treatment of ear disorders
IL212079A0 (en) Methods and devices for treating sleep apnea
IL213068A0 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
IL202015A0 (en) Methods and compositions for treating skin conditions
EP2379559A4 (en) Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2361089A4 (en) Compositions and methods for the treatment of altered -synuclein function
EP2509596A4 (en) Compounds and methods of treating ocular disorders
EP2334315A4 (en) Agents and methods for treatment of pain
ZA201100459B (en) Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders
HK1162366A1 (en) Devices and methods for treating and or preventing diseases
PL2300614T3 (en) Methods and compositions for treatment of mitochondrial disorders
IL218143A0 (en) Substituted heterocyclic derivatives for the treatment of pain and epilepsy
EP2271352A4 (en) Compositions and methods for treatment of neoplastic disease
EP2440205A4 (en) Iminosugars and methods of treating bunyaviral and togaviral diseases
EP2473046A4 (en) Iminosugars and methods of treating filoviral diseases
HK1157228A1 (en) Compositions and methods of treating amyloid disease
EP2456437A4 (en) Combinations of curcummoids and mtor inhibitors for the treatment of tauopathies
EP2421532A4 (en) Spiperone derivatives and methods of treating disorders
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
IL209947A0 (en) Compositions and methods for treating corneal inflammation
EP2370087A4 (en) Methods and compositions for the treatment of fluid retention disorders
EP2349469A4 (en) Devices and methods for treatment of myocardial conditions
HK1145282A1 (en) Treatment of sleep disorders
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110902

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/00 20060101ALI20120524BHEP

Ipc: A61P 13/10 20060101ALI20120524BHEP

Ipc: A61K 31/438 20060101AFI20120524BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130103